FeesSafety
Pluang+

Allarity Therapeutics secures U.S. patent for stenoparib dosing regimen, protecting treatment into 2045

Company Fundamentals
18 Nov 2026, 14:50 WIB
GlobeNewsWire
View Source
Bullish
Allarity Therapeutics secures U.S. patent for stenoparib dosing regimen, protecting treatment into 2045

Allarity Therapeutics has been granted a U.S. patent covering the twice-daily dosing regimen of its cancer drug stenoparib, with protection extending until 2045. This patent covers treatment methods for advanced ovarian cancer and other solid tumors, strengthening Allarity's intellectual property as it advances clinical trials. The patent supports the company's strategy to develop stenoparib alongside a companion diagnostic to identify patients most likely to benefit. This milestone boosts Allarity's potential for FDA approval and future partnerships.

Allarity Therapeutics' patent news is presented here with Health-sector market data from Pluang. For readers following this sector, as of Nov 18, 2026 19:21 WIB, 55 of 150 priced US Health stocks rose while 86 fell. Notable movers include DNA at USD 8.59 with a 3.25% gain, ABEO at USD 2.68 up 3.08%, and SLS at USD 18.61 down 2.82%.

More News

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
38 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgraded Charles Schwab to Strong Buy following strong growth in October 2026. Client assets rose 12% year over year to $13.27 trillion, with core net new assets surging 50% to $66.5 billion, a record for the month. Schwab also opened 4...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App